We are neuroimaging experts for neurological clinical trials, including Alzheimer’s disease, Parkinson’s disease and Huntington's disease.
We work closely with international commercial, clinical and academic partners to ensure we remain at the forefront of the clinical research industry in developing and validating unique, novel neuroimaging methods and image analysis techniques. Our goal is to provide ever more accurate and richer brain structural and functional information to further research into therapies for neurodegenerative diseases.
Partnering across all stages of your CNS trials – from participant eligibility and stratification, to ensuring patient safety, to assessing drug efficacy throughout your clinical study and beyond.
We are a recognised leader in volumetric MRI analysis. Our patented LEAP technology has been applied to thousands of datasets and provides accurate delineation of relevant brain structures while quantifying the volumes of over 150 structures in a single workflow.
We measure brain volume both cross-sectionally and longitudinally using our LEAP (Learning Embeddings for Atlas Propagation) or IXIQ.Ai pipeline, which provides the following measures:
• Global – making measurements on the whole brain
• Regional – measuring specific local brain regions
Molecular imaging biomarkers provide powerful insights into pathology and treatment response. We provide fully automated SUVR (Standardised Uptake Value Ratio) and dynamic analysis methods for the quantification of amyloid pathology from PET imaging. Additionally, our tau PET analysis allows us to quantify neurofibrillary tangles (NFT) distribution in different clinical groups or monitor longitudinal changes.
In Parkinson’s disease, Dopamine Transporter Single-Photon Emission Computed Tomography (DaT SPECT) scan imaging assesses dopamine transporter density, aiding in patient selection and stratification. Visual and quantitative reads, including striatal binding ratios, are delivered within a three-day turnaround.
Advanced MRI techniques are increasingly leveraged in CNS clinical trials to understand mechanisms that underlie many neurological disorders. IXICO's advanced MRI solutions include diffusion MRI, such as diffusion tensor imaging (DTI), arterial spin labelling (ASL), and functional MRI (fMRI).
We provide centralised neuroradiological reading of MRI scans to assess participant eligibility and monitor drug safety. Our platform provides a standardised, compliant and efficient workflow for capturing visual read results of MRI, SPECT and PET scans.
Let's talk about what you need. Contact us today.
Contact us